These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 21953282

  • 21. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T, Liu H, Liu Z, Li K, Qin R, Wang Y, Liu J, Li Z, Gao Q, Pan C, Yang F, Zhao W, Zhang Z, Xu Y.
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling.
    Wang LX, Frey MR, Kohli R.
    Front Endocrinol (Lausanne); 2021 Jul; 12():799648. PubMed ID: 35116006
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.
    Barrera F, Azócar L, Molina H, Schalper KA, Ocares M, Liberona J, Villarroel L, Pimentel F, Pérez-Ayuso RM, Nervi F, Groen AK, Miquel JF.
    Ann Hepatol; 2015 Jul; 14(5):710-21. PubMed ID: 26256900
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients.
    Koelfat KVK, Plummer MP, Schaap FG, Lenicek M, Jansen PLM, Deane AM, Olde Damink SWM.
    Hepatology; 2019 Jul; 70(1):308-318. PubMed ID: 30933374
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
    Simbrunner B, Hofer BS, Schwabl P, Zinober K, Petrenko O, Fuchs C, Semmler G, Marculescu R, Mandorfer M, Datz C, Trauner M, Reiberger T.
    Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Selective Regulation of FGF19 and FGF21 Expression by Cellular and Nutritional Stress.
    Shimizu M, Morimoto H, Maruyama R, Inoue J, Sato R.
    J Nutr Sci Vitaminol (Tokyo); 2015 Jun; 61(2):154-60. PubMed ID: 26052146
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis.
    Romain G, Tremblay S, Arena ET, Antunes LC, Covey S, Chow MT, Finlay BB, Menendez A.
    BMC Microbiol; 2013 Oct 29; 13():238. PubMed ID: 24165751
    [Abstract] [Full Text] [Related]

  • 40. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.
    Chignard N, Mergey M, Barbu V, Finzi L, Tiret E, Paul A, Housset C.
    Hepatology; 2005 Sep 29; 42(3):549-57. PubMed ID: 16037943
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.